iTeos Therapeutics stock price target lowered to $10 at Leerink Partners

iTeos Therapeutics (ITOS) is being acquired by privately-held Concentra Biosciences for $10 per share, a deal Leerink Partners expects to close despite representing a 2% discount to iTeos's pre-announcement trading price and a 19% discount to Leerink's post-wind down cash estimates. This transaction follows iTeos's decision to cease operations and sell assets after its belrestotug program failed clinical endpoints. While iTeos reported $624 million in cash at the end of Q1 2025, the deal implies $475 million cash at close, reflecting wind-down expenses. Leerink maintained a Market Perform rating, while Wedbush downgraded to Neutral and Piper Sandler reduced its price target, reflecting the company's strategic shift towards asset liquidation.

Analysis

iTeos Therapeutics (ITOS) is in a terminal phase, shifting from an operating biotech to an acquisition target following its decision to cease operations. The catalyst for this move was the failure of its belrestotug program to meet key clinical endpoints. The company is now being acquired by Concentra Biosciences for $10.00 per share, a price that Leerink Partners believes will be accepted despite representing a 19% discount to their estimated post-wind-down cash value of $12 per share. This valuation discrepancy is largely explained by significant wind-down expenses for its Belgium R&D operations, which reduce the company's Q1 2025 cash position of $624 million to an implied $475 million at deal close. The deal's closure is considered highly probable, as the top two shareholders, EcoR1 and Tang Capital, control approximately 38% of the company and are expected to support the transaction. Further upside for shareholders appears limited, with analysts expressing skepticism about any potential payout from the contingent value right (CVR) associated with asset sales due to the challenging market for out-licensing immuno-oncology assets.

Key Decisions for Investors

• Investors should consider the $10.00 per share acquisition price as the primary valuation anchor, as the deal is highly likely to close, effectively capping near-term upside.
• The stock is now a merger arbitrage play with a minimal spread, not a long-term biotech investment, given the cessation of all R&D and liquidation of assets.
• Do not factor in significant potential value from the Contingent Value Right (CVR), as analysis suggests a low probability of a payout from asset sales within the specified timeframe.
• Existing shareholders must weigh holding for the deal's completion against the opportunity cost of redeploying capital elsewhere, as further share price appreciation is unlikely.